Klemens Budde1, Bernard A Zonnenberg2, Michael Frost3, Wing Cheung4, Shweta Urva4, Thomas Brechenmacher5, Karen Stein4, David Chen4, John Christopher Kingswood6, John J Bissler7. 1. Charité Universitätsmedizin, Berlin, Germany. 2. Universitair Medisch Centrum, Utrecht, The Netherlands. 3. Minnesota Epilepsy Group, St Paul, Minnesota. 4. Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA. 5. Novartis Pharma Corporation, S.A.S., Rueil-Malmaison, France. 6. Royal Sussex County Hospital, Brighton, UK. 7. Lebonheur Children's Hospital and the University of Tennessee, Memphis, Tennessee, USA.
Abstract
AIMS: The purpose was to determine the exposure-response relationship of everolimus in patients with angiomyolipoma from the EXIST-2 trial and to analyze the correlation between exposure and plasma concentrations of angiogenic biomarkers in these patients. METHODS:One hundred and eighteen patients with angiomyolipoma associated with tuberous sclerosis complex (TSC) or sporadic lymphangioleiomyomatosis (sLAM) were randomly assigned 2 : 1 to receive everolimus 10 mg (n = 79) or placebo (n = 39) once daily. Blood samples for determining everolimus concentration were collected at weeks 2, 4, 12, 24 and 48 during double-blind treatment. Plasma samples for biomarker analysis were collected at baseline and weeks 4, 12, 24, 36, 48 and at the end of treatment. Concentrations of eight angiogenic biomarkers associated with tumour growth were determined by enzyme-linked immunosorbent assay (ELISA). RESULTS:Peak and trough concentrations of everolimus in blood remained stable over time and similar to those reported in other indications. Substantial pharmacodynamic effects were observed in the everolimus, but not placebo, arm for three biomarkers: After 24 weeks of treatment, reduction of vascular endothelial growth factor D (VEGF-D) and collagen type IV (COL-IV) (mean fold-changes with 95% confidence intervals [CI] were 0.36 [0.33, 0.40], and 0.54 [0.51, 0.57], respectively, P < 0.001 for both), along with increased VEGF-A (mean fold-change of 1.59 [1.39, 1.80], P < 0.001), were seen. Furthermore, baseline VEGF-D and COL-IV levels were associated with angiomyolipoma size at baseline and with angiomyolipoma response to everolimus. CONCLUSIONS: These findings suggest that plasma angiogenic markers may provide an objective measure of patient response to everolimus.
RCT Entities:
AIMS: The purpose was to determine the exposure-response relationship of everolimus in patients with angiomyolipoma from the EXIST-2 trial and to analyze the correlation between exposure and plasma concentrations of angiogenic biomarkers in these patients. METHODS: One hundred and eighteen patients with angiomyolipoma associated with tuberous sclerosis complex (TSC) or sporadic lymphangioleiomyomatosis (sLAM) were randomly assigned 2 : 1 to receive everolimus 10 mg (n = 79) or placebo (n = 39) once daily. Blood samples for determining everolimus concentration were collected at weeks 2, 4, 12, 24 and 48 during double-blind treatment. Plasma samples for biomarker analysis were collected at baseline and weeks 4, 12, 24, 36, 48 and at the end of treatment. Concentrations of eight angiogenic biomarkers associated with tumour growth were determined by enzyme-linked immunosorbent assay (ELISA). RESULTS: Peak and trough concentrations of everolimus in blood remained stable over time and similar to those reported in other indications. Substantial pharmacodynamic effects were observed in the everolimus, but not placebo, arm for three biomarkers: After 24 weeks of treatment, reduction of vascular endothelial growth factor D (VEGF-D) and collagen type IV (COL-IV) (mean fold-changes with 95% confidence intervals [CI] were 0.36 [0.33, 0.40], and 0.54 [0.51, 0.57], respectively, P < 0.001 for both), along with increased VEGF-A (mean fold-change of 1.59 [1.39, 1.80], P < 0.001), were seen. Furthermore, baseline VEGF-D and COL-IV levels were associated with angiomyolipoma size at baseline and with angiomyolipoma response to everolimus. CONCLUSIONS: These findings suggest that plasma angiogenic markers may provide an objective measure of patient response to everolimus.
Authors: D N Franz; A Brody; C Meyer; J Leonard; G Chuck; S Dabora; G Sethuraman; T V Colby; D J Kwiatkowski; F X McCormack Journal: Am J Respir Crit Care Med Date: 2001-08-15 Impact factor: 21.405
Authors: Corey J Cudzilo; Rhonda D Szczesniak; Alan S Brody; Mantosh S Rattan; Darcy A Krueger; John J Bissler; David N Franz; Francis X McCormack; Lisa R Young Journal: Chest Date: 2013-08 Impact factor: 9.410
Authors: Sandra L Dabora; David Neal Franz; Stephen Ashwal; Arthur Sagalowsky; Francis J DiMario; Daniel Miles; Drew Cutler; Darcy Krueger; Raul N Uppot; Rahmin Rabenou; Susana Camposano; Jan Paolini; Fiona Fennessy; Nancy Lee; Chelsey Woodrum; Judith Manola; Judy Garber; Elizabeth A Thiele Journal: PLoS One Date: 2011-09-06 Impact factor: 3.240
Authors: Zhao W Yeoh; Vidya Navaratnam; Rupesh Bhatt; Ian McCafferty; Richard B Hubbard; Simon R Johnson Journal: Orphanet J Rare Dis Date: 2014-10-03 Impact factor: 4.123
Authors: Maria Fankhauser; Nicole Bechmann; Michael Lauseker; Judith Goncalves; Judith Favier; Barbara Klink; Doreen William; Laura Gieldon; Julian Maurer; Gerald Spöttl; Petra Rank; Thomas Knösel; Michael Orth; Christian G Ziegler; Elke Tatjana Aristizabal Prada; German Rubinstein; Martin Fassnacht; Christine Spitzweg; Ashley B Grossman; Karel Pacak; Felix Beuschlein; Stefan R Bornstein; Graeme Eisenhofer; Christoph J Auernhammer; Martin Reincke; Svenja Nölting Journal: Endocrinology Date: 2019-11-01 Impact factor: 4.736
Authors: Heng Du; John R Dreier; Mahsa Zarei; Chin-Lee Wu; Roderick W Bronson; David J Kwiatkowski Journal: Hum Mol Genet Date: 2018-12-15 Impact factor: 6.150
Authors: Elke Tatjana Aristizabal Prada; Gerald Spöttl; Julian Maurer; Michael Lauseker; Eva Jolanthe Koziolek; Jörg Schrader; Ashley Grossman; Karel Pacak; Felix Beuschlein; Christoph Joseph Auernhammer; Svenja Nölting Journal: Endocr Relat Cancer Date: 2018-06-12 Impact factor: 5.678
Authors: Peter J Klover; Rajesh L Thangapazham; Jiro Kato; Ji-An Wang; Stasia A Anderson; Victoria Hoffmann; Wendy K Steagall; Shaowei Li; Elizabeth McCart; Neera Nathan; Joshua D Bernstock; Matthew D Wilkerson; Clifton L Dalgard; Joel Moss; Thomas N Darling Journal: Elife Date: 2017-07-11 Impact factor: 8.140